These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36890284)

  • 21. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.
    Deenen MJ; Tol J; Burylo AM; Doodeman VD; de Boer A; Vincent A; Guchelaar HJ; Smits PH; Beijnen JH; Punt CJ; Schellens JH; Cats A
    Clin Cancer Res; 2011 May; 17(10):3455-68. PubMed ID: 21498394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events.
    Wigle TJ; Povitz BL; Medwid S; Teft WA; Legan RM; Lenehan J; Nevison S; Panuganty V; Keller D; Mailloux J; Siebring V; Sarma S; Choi YH; Welch S; Winquist E; Schwarz UI; Kim RB
    Clin Transl Sci; 2021 Jul; 14(4):1338-1348. PubMed ID: 33620159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase.
    Falvella FS; Caporale M; Cheli S; Martinetti A; Berenato R; Maggi C; Niger M; Ricchini F; Bossi I; Di Bartolomeo M; Sottotetti E; Bernardi FF; de Braud F; Clementi E; Pietrantonio F
    Int J Mol Sci; 2015 Apr; 16(4):8884-95. PubMed ID: 25906475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotype.
    Medwid S; Wigle TJ; Kim RB
    Cancer Chemother Pharmacol; 2023 Jan; 91(1):97-102. PubMed ID: 36357798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.
    Lunenburg CATC; Henricks LM; Guchelaar HJ; Swen JJ; Deenen MJ; Schellens JHM; Gelderblom H
    Eur J Cancer; 2016 Feb; 54():40-48. PubMed ID: 26716401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine.
    García-González X; Kaczmarczyk B; Abarca-Zabalía J; Thomas F; García-Alfonso P; Robles L; Pachón V; Vaz Á; Salvador-Martín S; Sanjurjo-Sáez M; López-Fernández LA
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):45-54. PubMed ID: 32529295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.
    Toffoli G; Giodini L; Buonadonna A; Berretta M; De Paoli A; Scalone S; Miolo G; Mini E; Nobili S; Lonardi S; Pella N; Lo Re G; Montico M; Roncato R; Dreussi E; Gagno S; Cecchin E
    Int J Cancer; 2015 Dec; 137(12):2971-80. PubMed ID: 26099996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score.
    Henricks LM; Lunenburg CA; Meulendijks D; Gelderblom H; Cats A; Swen JJ; Schellens JH; Guchelaar HJ
    Pharmacogenomics; 2015; 16(11):1277-86. PubMed ID: 26265346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency.
    Etienne-Grimaldi MC; Pallet N; Boige V; Ciccolini J; Chouchana L; Barin-Le Guellec C; Zaanan A; Narjoz C; Taieb J; Thomas F; Loriot MA;
    Eur J Cancer; 2023 Mar; 181():3-17. PubMed ID: 36621118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: a lethal case with a new variant.
    Del Re M; Quaquarini E; Sottotetti F; Michelucci A; Palumbo R; Simi P; Danesi R; Bernardo A
    Pharmacogenomics; 2016; 17(1):5-9. PubMed ID: 26651493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.
    van Kuilenburg AB; Meijer J; Maurer D; Dobritzsch D; Meinsma R; Los M; Knegt LC; Zoetekouw L; Jansen RL; Dezentjé V; van Huis-Tanja LH; van Kampen RJ; Hertz JM; Hennekam RC
    Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):721-730. PubMed ID: 28024938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Near Miss or Standard of Care?
    Winquist LE; Sanatani M; Kim RB; Winquist E
    Curr Oncol; 2020 Dec; 28(1):94-97. PubMed ID: 33704179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping.
    White C; Scott RJ; Paul C; Ziolkowski A; Mossman D; Fox SB; Michael M; Ackland S
    Clin Pharmacol Ther; 2022 Oct; 112(4):791-802. PubMed ID: 35607723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a
    Ockeloen CW; Raaijmakers A; Hijmans-van der Vegt M; Bierau J; de Vos-Geelen J; Willemsen AE; van den Bosch BJ; Coenen MJ
    J Oncol Pharm Pract; 2023 Jan; 29(1):5-13. PubMed ID: 34797200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.
    Deenen MJ; Meulendijks D; Cats A; Sechterberger MK; Severens JL; Boot H; Smits PH; Rosing H; Mandigers CM; Soesan M; Beijnen JH; Schellens JH
    J Clin Oncol; 2016 Jan; 34(3):227-34. PubMed ID: 26573078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.
    Stavraka C; Pouptsis A; Okonta L; DeSouza K; Charlton P; Kapiris M; Marinaki A; Karapanagiotou E; Papadatos-Pastos D; Mansi J
    Breast Cancer Res Treat; 2019 Jun; 175(2):511-517. PubMed ID: 30746637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implementation and clinical benefit of DPYD genotyping in a Danish cancer population.
    Paulsen NH; Pfeiffer P; Ewertz M; Fruekilde PBN; Feddersen S; Holm HS; Bergmann TK; Qvortrup C; Damkier P
    ESMO Open; 2023 Feb; 8(1):100782. PubMed ID: 36791638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients.
    He YF; Wei W; Zhang X; Li YH; Li S; Wang FH; Lin XB; Li ZM; Zhang DS; Huang HQ; Hu B; Jiang WQ
    J Clin Pharm Ther; 2008 Jun; 33(3):307-14. PubMed ID: 18452418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene.
    Ofverholm A; Arkblad E; Skrtic S; Albertsson P; Shubbar E; Enerbäck C
    Clin Biochem; 2010 Feb; 43(3):331-4. PubMed ID: 19822137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy.
    Hamzic S; Aebi S; Joerger M; Montemurro M; Ansari M; Amstutz U; Largiadèr C
    Swiss Med Wkly; 2020 Nov; 150():w20375. PubMed ID: 33232506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.